- Home
- RENB vs RPTX Comparison
RENB vs RPTX Comparison
Compare RENB & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- RPTX
- Stock Information
- Founded
- RENB 2011
- RPTX 2016
- Country
- RENB United States
- RPTX Canada
- Employees
- RENB N/A
- RPTX N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- RENB Health Care
- RPTX Health Care
- Exchange
- RENB Nasdaq
- RPTX Nasdaq
- Market Cap
- RENB 57.7M
- RPTX 69.2M
- IPO Year
- RENB N/A
- RPTX 2020
- Fundamental
- Price
- RENB $0.17
- RPTX $1.75
- Analyst Decision
- RENB
- RPTX Strong Buy
- Analyst Count
- RENB 0
- RPTX 3
- Target Price
- RENB N/A
- RPTX $4.50
- AVG Volume (30 Days)
- RENB 993.7K
- RPTX 97.5K
- Earning Date
- RENB 11-13-2025
- RPTX 11-06-2025
- Dividend Yield
- RENB N/A
- RPTX N/A
- EPS Growth
- RENB N/A
- RPTX N/A
- EPS
- RENB N/A
- RPTX N/A
- Revenue
- RENB N/A
- RPTX $250,000.00
- Revenue This Year
- RENB N/A
- RPTX N/A
- Revenue Next Year
- RENB N/A
- RPTX N/A
- P/E Ratio
- RENB N/A
- RPTX N/A
- Revenue Growth
- RENB N/A
- RPTX N/A
- 52 Week Low
- RENB $0.17
- RPTX $0.89
- 52 Week High
- RENB $2.10
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- RENB 31.45
- RPTX 63.55
- Support Level
- RENB $0.18
- RPTX $1.66
- Resistance Level
- RENB $0.22
- RPTX $1.83
- Average True Range (ATR)
- RENB 0.02
- RPTX 0.06
- MACD
- RENB -0.00
- RPTX 0.00
- Stochastic Oscillator
- RENB 0.53
- RPTX 68.00
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.